| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/28/1999 | EP0874639A4 Peptide inhibitors of a phosphotyrosine-binding domain containing protein |
| 07/28/1999 | EP0766665B1 Metalloproteinase inhibitors |
| 07/28/1999 | EP0743958A4 Non-viral vector |
| 07/28/1999 | EP0678122B1 Recombinant anti-vla4 antibody molecules |
| 07/28/1999 | EP0643693B1 Reversal of multi-drug resistance by triphenyl-piperidine derivatives |
| 07/28/1999 | EP0531419B1 Bistriazenes as chemotherapeutic agents |
| 07/28/1999 | CN1224464A Growth factor and genetic sequence encoding same |
| 07/28/1999 | CN1224428A Cellular injury response element and uses thereof |
| 07/28/1999 | CN1224357A Aqueous formulations of peptides |
| 07/28/1999 | CN1224356A Non-aqueous protic peptide formulations |
| 07/28/1999 | CN1223888A Anticancer oral liquid contg. lipolytic enzyme |
| 07/28/1999 | CN1223886A Pathogenic factor eliminating and healthy energy supporting anticancer medicine |
| 07/28/1999 | CN1223883A Anti-lung cancer medicine |
| 07/27/1999 | US5929226 Three or more but not all nucleotides are connected with methylphosphonothioate linkages where sulfur is not bridging atom; increased resistance to nucleases, increased duplex stability |
| 07/27/1999 | US5929224 Dna encoding human white blood cell activating proteins; useful in diagnosis as anticarcinogenic agents |
| 07/27/1999 | US5929213 Antibodies to growth differentiation factor-12 |
| 07/27/1999 | US5929112 Use in pharmaceuticals or cosmetics as antioxidants, improved bioavailability |
| 07/27/1999 | US5929105 Ethylene glycol esters as photoactive agents |
| 07/27/1999 | US5929103 Anticarcinogenic agents |
| 07/27/1999 | US5929063 Mercapto and seleno derivatives as inhibitors of nitric oxide synthase |
| 07/27/1999 | US5929056 Accesible from readily available starting materials to be used for wound healing and in cosmetics |
| 07/27/1999 | US5929048 Treatment of conditions and disease |
| 07/27/1999 | US5929046 Pyrimidine and purine derivatives and their use in treating tumour cells |
| 07/27/1999 | US5929040 Method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders |
| 07/27/1999 | US5928939 Genetic engineering |
| 07/27/1999 | US5928938 Isolated peptides which complex with HLA-Cw*16 molecules, and uses thereof |
| 07/27/1999 | US5928913 Herpes virus amplicon coding for antigen or immunomodulatory protein with replication-deficient helper herpes virus; for gene therapy and vaccines |
| 07/27/1999 | US5928899 Cell division regulators |
| 07/27/1999 | US5928874 Nek1-related protein kinase |
| 07/27/1999 | US5928647 Immunization with non-replicating protein antigens. the compositions of the invention comprise a particulate-protein complex |
| 07/27/1999 | US5928641 Having binding specificity for crossreactive epitopes shared by endoglin expressed on human vascular endothelial cells and endoglin expressed on murine vascular endothelial cells |
| 07/27/1999 | US5928639 Immunotherapy of cancer with allogeneic lymphocytes |
| 07/27/1999 | CA2215327C Formulations for lipophilic compounds |
| 07/27/1999 | CA2166721C Bicyclic tetrahydro pyrazolopyridines |
| 07/22/1999 | WO1999036540A1 Human chemokine and its use for detection and treatment of breast disease |
| 07/22/1999 | WO1999036535A1 Apo-2 ligand |
| 07/22/1999 | WO1999036531A1 Gtpase derived from human lymph nodes that effects the morphology and cytoskeleton organization of endothelial cells |
| 07/22/1999 | WO1999036514A1 Methods and compositions for gene delivery |
| 07/22/1999 | WO1999036512A1 Secreted proteins and polynucleotides encoding them |
| 07/22/1999 | WO1999036437A1 Antibody/receptor targeting moiety for enhanced delivery of armed ligand |
| 07/22/1999 | WO1999036436A1 FATTY ACID SYNTHASE mRNA BINDING PROTEIN |
| 07/22/1999 | WO1999036413A1 Novel crystalline complexes of baccatin iii with imidazole, 2-methylimidazole or isopropanol |
| 07/22/1999 | WO1999036409A1 Metabolically inert anti-inflammatory and anti-tumor antifolates |
| 07/22/1999 | WO1999036105A2 USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE |
| 07/22/1999 | WO1999036094A2 Composition and method for treating metastatic tumors or cancer induced by cells expressing sv40 tumor antigen |
| 07/22/1999 | WO1999036085A1 Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes |
| 07/22/1999 | WO1999036076A1 Composition containing propargylamine for enhancing cancer therapy |
| 07/22/1999 | WO1999036063A2 Vanadium (iv) metallocene complexes having spermicidal activity |
| 07/22/1999 | WO1999036056A1 Lipomatrix preparation |
| 07/22/1999 | WO1999030157A3 Neuropilins in methods for diagnosis and prognosis of cancer |
| 07/22/1999 | WO1999029309A3 2,2'-bi-1h-pyrrole derivatives useful in the treatment of leukemia brought on by htlv-i |
| 07/22/1999 | WO1999027958A3 Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination |
| 07/22/1999 | WO1999024052A3 Use of protein h as cytostatic agent |
| 07/22/1999 | WO1998059040A3 Human catalytic telomerase sub-unit and its diagnostic and therapeutic use |
| 07/22/1999 | WO1998046276A8 Chelating agents |
| 07/22/1999 | CA2318693A1 Composition containing propargylamine for enhancing cancer therapy |
| 07/22/1999 | CA2318663A1 Methods and compositions for gene delivery |
| 07/22/1999 | CA2318557A1 Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes |
| 07/22/1999 | CA2318556A1 Lipomatrix preparation |
| 07/22/1999 | CA2318284A1 Antibody/receptor targeting moiety for enhanced delivery of armed ligand |
| 07/22/1999 | CA2318231A1 Use of radiolabeled monoclonal igm in therapy for cancer and autoimmune disease |
| 07/22/1999 | CA2318159A1 Vanadium (iv) metallocene complexes having spermicidal activity |
| 07/22/1999 | CA2317810A1 Human chemokine and its use for detection and treatment of breast disease |
| 07/22/1999 | CA2317728A1 Novel crystalline complexes of baccatin iii with imidazole, 2-methylimidazole or isopropanol |
| 07/22/1999 | CA2317392A1 Secreted proteins and polynucleotides encoding them |
| 07/22/1999 | CA2315299A1 Fatty acid synthase mrna binding protein |
| 07/21/1999 | EP0929675A2 Nucleotide and protein sequence of mammastatin and methods of use |
| 07/21/1999 | EP0929673A2 Tumor proteins |
| 07/21/1999 | EP0929672A1 Human gtp binding protein gamma-3 |
| 07/21/1999 | EP0929670A1 P-selectin ligand proteins |
| 07/21/1999 | EP0929579A1 Monoclonal antibodies against a human act and serine protease complex |
| 07/21/1999 | EP0929578A1 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
| 07/21/1999 | EP0929575A1 Novel human growth factors |
| 07/21/1999 | EP0929571A1 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators |
| 07/21/1999 | EP0929570A1 Modified cytostatic agents |
| 07/21/1999 | EP0929554A1 Spiro-azacyclic derivatives, their preparation and their use as tachykinin antagonists |
| 07/21/1999 | EP0929553A1 Pyrimidine derivatives and processes for the preparation thereof |
| 07/21/1999 | EP0929552A1 Acridone derivatives and method of preparation of 8-hydroxy imidazoacridinone derivatives |
| 07/21/1999 | EP0929549A1 Substituted 2-pyrimidineamines, their preparation and their use as proteine kinase inhibitors |
| 07/21/1999 | EP0929545A1 Tricyclic inhibitors of farnesyl protein transferase |
| 07/21/1999 | EP0929544A1 Tricyclic antitumor compounds being farnesyl protein transferase inhibitors |
| 07/21/1999 | EP0929542A1 Compounds for and a method of inhibiting matrix metalloproteinases |
| 07/21/1999 | EP0929538A1 O?2 -arylated or o?2 -glycosylated 1-substituted diazen-1-ium-1,2-diolates and o?2 -substituted 1- (2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates |
| 07/21/1999 | EP0929530A1 Quinazoline derivatives and pharmaceutical compositions containing them |
| 07/21/1999 | EP0929520A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease |
| 07/21/1999 | EP0929318A2 Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same |
| 07/21/1999 | EP0929308A1 Pharmaceutical composition containing an embryonic or gravid uterus extract as an active substance and relative preparation process |
| 07/21/1999 | EP0929300A2 Cyanidin compositions and therapeutic and diagnostic uses therefor |
| 07/21/1999 | EP0929293A1 Liposomes containing a cisplatin compound |
| 07/21/1999 | EP0765327B1 Pyrazolo and pyrrolopyridines |
| 07/21/1999 | EP0745092B1 Peptide inhibitors of urokinase receptor activity |
| 07/21/1999 | CN1223690A Antiangiogenic peptides derived from plasminogen, its coded polynucleotide and method of inhibiting vascularization |
| 07/21/1999 | CN1223654A N-[4-(heteroarylmethyl) phenyl]-heteroarylamines |
| 07/21/1999 | CN1223651A Substituted indazole derivatives and their use as phosphodiesterase (PDE) type IV and tumor necrosis factor (TNF) inhibitors |
| 07/21/1999 | CN1223643A Prenyl transferase inhibitors |
| 07/21/1999 | CN1223642A Inhibitors of prenyl transferases |
| 07/21/1999 | CN1223145A Carcinoembryonic antigen gene engineering antiboy CL-3-scFv |
| 07/21/1999 | CN1044249C Matrix metalloprotease inhibitors |
| 07/21/1999 | CN1044239C Sulfonylurea derivatives, method for prepn. of same and use thereof |
| 07/21/1999 | CN1044234C Substituted phenylimidazolidines, their preparation process, their use as medicaments and the pharmaceutical compositions containing them |